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Summary 
 
 
  
 
1-(4-Fluorophenyl)propan-2-amine (4-fluoroamphetamine, 4-FA) underwent a critical review in 
November 2015 at the 37th meeting of the WHO Expert Committee on Drug Dependence. The 
Committee recommended that 4-FA not be placed under international control at that time due to 
insufficiency of data regarding dependence, abuse and risks to public health but be kept under 
surveillance. This review represents an update. 
 
4-FA is a psychomotor stimulant first synthesized in the early 1940s. The European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) received the first formal notification of the 
detection of 4-FA in Europe in December 2008 although its presence has been noted since at least 
2007. In Europe, it has been found in tablets sold as ‘ecstasy’/MDMA, paste or powder sold as 
amphetamine. It has also been detected as an adulterant present in other illicit controlled substances. 
The EMCDDA has been notified of seizures from various locations in Europe since 2008. In the 
Netherlands, 4-FA has recently established itself as a drug of choice (powdered form, tablets and 
capsules) in a subpopulation of recreational drug users associated with clubs and music festivals. 4-
FA appears to be most commonly administered orally or by nasal insufflation (snorting).  
 
Data indicate that 4-FA may be able to inhibit monoamine oxidase and that it functions as a 
substrate-type releasing agent of dopamine, norepinephrine and serotonin. It has been shown to 
display amphetamine-like features in vivo and in vitro, which suggests that abuse liability might 
extend to humans. Further research is warranted to investigate the extent to which 4-FA displays a 
potential dependence in both animals in humans. Case report data in the scientific literature that 
unambiguously confirm a causal relationship between adverse effects of 4-FA and its presence in 
biofluids are limited to only a relatively small number of cases. In cases where this information is 
available, reported clinical features were associated with those of a sympathomimetic toxidrome. 
Information about a global perspective is missing. However, reports received from data monitoring 
systems in the Netherlands indicate increased use and popularity alongside increased numbers of 
notifications associated with severe adverse drug effects including serious cardiovascular toxicity. 
 
Following a risk assessment carried out by the Dutch Centre for the Assessment and Monitoring of 
new drugs (CAM), it was concluded that the risk to individual health was small to moderate but with 
high risk for acute toxicity especially in subpopulations associated with clubbing. The risk to public 
health was deemed moderate to large based on rising trends in use number of health incidents. The 
overall risk score of 4-FA was considered high, which led to 4-FA being placed under legislative 
control.  
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1.   Substance identification  
A. International Nonproprietary Name (INN) 
Not available. 
B. Chemical Abstract Service (CAS) Registry Number 
459-02-9 (free base) 
64609-06-9 (hydrochloride salt) 
72522-20-4 ((αR)-free base) 
788123-23-9 ((αS)-free base) 
127515-13-3 ((αS)- hydrochloride salt) 
72522-24-8 ((αR)- hydrochloride salt) 
1419922-92-1 (1,2,3,4,5,6-13C6-free base) 
59963-24-5 (D-mannopyranose, 1-(hydrogen sulfate)) 
153506-17-3 (4-(fluoro-18F)) 
72522-20-4 (L-leucine, N-acetyl- compd. with (αR)-4-fluoro-α-
methylbenzeneethanamine, 1:1) 
788123-23-9 (L-leucine, N-acetyl- compd. with (αS)-4-fluoro-α-
methylbenzeneethanamine, 1:1) 
1782279-11-1 (d5-hydrochloride salt) 
1783027-85-9 (d5-free base) 
C. Other Chemical Names 
1-(4-Fluorophenyl)-2-propanamine, 1-(p-fluorophenyl)-2-aminopropane, 2-amino-
1-(4'-fluorophenyl)propane, 2-amino-1-(4'-fluorophenyl)propane, 2-amino-1-(p-
fluorophenyl)propane, 2-amino-1-(para-fluorophenyl)propane, p-fluoro-α-
methylphenethylamine, 2-(4-fluorophenyl)-1-methylethylamine, 2-(4-fluoro-
phenyl)-1-methyl-ethylamine, α-methyl-β-(4-fluorophenyl)ethylamine, α-methyl-β-
(p-fluorophenyl)ethylamine, α-methyl-p-fluorophenethylamine, 1-(4-
fluorophenyl)prop-2-ylamine, 1-(4-fluorophenyl)-2-propylamine, 1-(4-
fluorobenzyl)ethylamine, 1-p-fluorophenyl-2-propylamine, p-fluoro-α-methyl-
phenethylamine, para-fluoro-α-methyl-phenethylamine, 4-fluoro-α-methyl-
phenethylamine, 4-fluoroamphetamine, p-fluoroamphetamine, 
parafluoroamphetamine, PFA, 4-F-A, PAL-303, p-FA, P-FMP, 4-FMP, 4FMP, 4-
FA. 
D. Trade Names 
Not available. 
E. Street Names 
Flux, Fifa. 4-Fluo, Flo, RDJ, 4-Flava. 
F. Physical Appearance 
4-Fluoroamphetamine (4-FA) hydrochloride is a white crystalline powder. 
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G. WHO Review History 
4-FA underwent a critical review in November 2015 at the 36th meeting of the WHO 
Expert Committee on Drug Dependence.1 The Committee recommended that 4-FA 
not be placed under international control at that time due to insufficiency of data 
regarding dependence, abuse and risks to public health but be kept under 
surveillance.2 
 
2. Chemistry 
A. Chemical Name 
IUPAC Name: 1-(4-Fluorophenyl)propan-2-amine 
CA Index Name: 4-Fluoro-α-methyl-benzeneethanamine 
B. Chemical Structure 
Free base: 
 
Note: Asterisk (*) refers to a chiral centre 
 
Molecular Formula: C9H12FN (free base) 
Molecular Weight: 153.20 g/mol  
C. Stereoisomers 
The presence of a chiral center at the α-carbon of the side chain gives rise to the 
enantiomeric pair of (S)-4-FA and (R)-4-FA, respectively. However, 4-FA is most 
likely to be available as the racemic mixture. 
D. Methods and Ease of Illicit Manufacturing 
4-FA may be obtained from a variety of synthetic methods that are commonly 
employed for the preparation of amphetamine (e.g.3). A classic approach might 
include the use of the 1-(4-fluorophenyl)propan-2-one (4-fluorobenzyl methyl 
ketone) (a) and exposure to reductive conditions (i) (e.g. using formamide4) to give 
racemic 4-FA (b). Depending on the availability of starting materials, precursor (a) 
may be obtained from a variety of synthetic procedures. Another common approach 
includes the reduction of the nitroalkene intermediate 1-fluoro-4-(2-nitroprop-1-en-
1-yl)benzene5-9 (c) where 4-fluorobenzaldehyde may serve as the starting material. 
Enantiomerically pure forms of 4-FA have been prepared with the help of 
enzymes8, 10-18 and a number of chemical methods have also been reported.6, 9, 19-21 
Alternative suggestions for the preparation of 4-FA have been published.22, 23 The 
EMCDDA received information in 2009 about some 4-FA samples analyzed by the 
Forensic Science Service. The presence of specific impurities were associated with 
the Leuckart synthesis, which pointed to the possible use of 4-fluorobenzyl methyl 
ketone) (a) as the starting material.24 
 
NH2
CH3
*
F
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E. Chemical Properties 
Melting point 
 
Hydrochloride salt: 156–157 °C (dry acetone)4 
Hydrochloride salt: 152–154 °C6 
Hydrochloride salt: 152–154 °C22 
Hydrochloride salt: 152–154 °C23 
(αS)-Hydrochloride salt: 195–198 °C6 
(αR)-Hydrochloride salt: 195–197 °C6 
Hydrochloride salt: 156.9 °C25 
 
Boiling point 
 
Free base: 95–96 °C (17 mmHg)4 
Free base: 78 °C (10 mmHg) 6 
Free base: 96 °C (19.5 mmHg)23 
Free base: 90 °C22 
 
Solubility 
 
~Ten mg/ml in phosphate-buffered saline (pH 7.2); ~20 mg/ml in ethanol; ~30 
mg/ml in dimethylformamide and dimethyl sulfoxide.26 
 
F. Identification and Analysis  
Chemical and analytical data are abundantly available. 4-FA has also been employed 
for analytical purposes and featured in a range of routine methods of analysis 
associated with forensic and clinical investigations (Annex 2). Analytical challenges, 
especially when dealing with low concentrations encountered in biological matrices, 
might arise when attempting to differentiate 4-FA from its other two regioisomers 2-
FA and 3-FA. The availability of all three substances used as standard reference 
material would be recommended.   
 
i
(a) (b)
F
O
Various routes NH2
CH3
*
F
ii
(c) (b)
F
NO2 NH2
CH3
*
F
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3. Ease of Convertibility Into Controlled Substances 
No information available. 
 
4. General Pharmacology 
4-FA is a ring-substituted amphetamine with psychostimulant properties. From a contextual 
perspective, earlier research involving 4-FA is related to work on substances with pressor 
effects (e.g. ephedrine derivatives), in addition to research on potential appetite suppressants 
(e.g. fenfluramine or phenmetrazine) and other substances known to interact with the 
monoaminergic system, such as L-deprenyl or 4-chloroamphetamine.   
 
A. Routes of administration and dosage 
4-FA appears to be most commonly administered orally or by nasal insufflation 
(snorting) although the latter has also been associated with intense intranasal burning 
sensations and pain.27-29 A case of intravenous injection has also been mentioned in 
a patient undergoing opioid maintenance treatment.30 A recent survey of 4-FA users 
in the Netherlands revealed a range of dosage levels that may be encountered: 50–
100 mg (44 participants, 17.6%), 100–150 mg (105 participants, 42.2%), more than 
150 mg (48 participants, 19.2%, the remainder did not know).29 Some anecdotal 
reports indicate that higher doses might also be used.27, 31 Somewhat comparable 
doses have been described for oral administration elsewhere: ‘light’ 50-70 mg, 
‘common’ 70-110 mg; ‘heavy’ 115-150.32 Experience reports, either involving 4-FA 
alone or in combination with other substances are available, for example, on the 
Erowid website.33 Examples can be found in the patent literature where 4-FA was 
captured as a potential ingredient in pharmaceutical formulations.34-37 The analysis 
of three capsules collected in the Netherlands revealed the presence of 112 mg, 156 
mg and 179 mg 4-FA.38    
 
B. Pharmacokinetics 
Information collected from systematic studies in humans is lacking. 4-FA has been 
identified as one of several metabolites formed in male Sprague-Dawley rat brain in 
following subcutaneous and intracerebral of para-fluoro-deprenyl.39 A transient, i.e. 
short-lasting, reduction of serotonin levels was observed in male albino Wistar rat 
brain homogenates after administration of a 0.1 mmol/kg dose. Based on the analysis 
of drug concentration levels within the first four hours, a half-life of 3.7 h was 
calculated for 4-FA which compared to about 1 h in the case of amphetamine in the 
rat brain.40 Intravenous injection of 4-[18F]A into female CF-1 mice revealed that 
uptake into brain tissue was detected after 5 minutes (% does/organ:  liver > kidneys 
> lungs > small intestines > brain > spleen) followed by a rapid decline at the 30 min 
and 60 min mark.41 Duration of effects obtained from self-reports of 4-FA users: less 
than 4 hours (57 participants, 22.9%), 4–6 hours (110 participants, 44.2%); 6–8 hours 
(54 participants, 21.7%) and more than 8 hours (28 participants, 11.2%).29 Duration 
of effects (all routes of administration) have also been estimated as follows: 30-90 
min for onset, 4-8 h duration and 1-24 hours after effects.32  
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C. Pharmacodynamics 
As summarized in Tables 1 and 2, earlier work pointed toward interactions with the 
monoaminergic system and data obtained from studies in more recent years supports 
the suggestion that 4-FA functions as a substrate-type releasing agent of dopamine 
(DA), norepinephrine (NE) and serotonin (5-HT) and that it displays amphetamine-
like features in a number of in vivo and in vitro assays. 4-FA induces locomotor 
activity in mice and is associated with DA release in rat striatum and rat nucleus 
accumbens.42, 43 Drug discrimination studies performed in rats showed that 4-FA 
substituted for the 5-HT releaser fenfluramine44 although this was not confirmed in 
rats trained to discriminate between the 5-HT releasing agents (+)-MBDB, 5-
methoxy-6-methyl-2-aminoindan (MMAI) and saline. In this case, 4-FA fully 
mimicked (+)-amphetamine instead.42 It has recently been shown that 4-FA differed 
from (+)-amphetamine in its ability to result in higher 5-HT dialysate concentrations. 
These levels were obtained from rat nucleus accumbens and correlated with 
diminished motor stimulant activity, which led to the hypothesis that 5-HT release 
might be able to dampen the stimulant effects of amphetamine-type substances that 
are mediated by DA.43 Some user reports indicate that 4-FA might show pro-social 
effects in humans that might share some overlap with MDMA.29, 45 Recent in-vitro 
investigations involving various monoamine transporter uptake inhibition and release 
assays suggest that 4-FA displays catecholamine selective properties at NET and 
DAT with significantly less pronounced interactions with the serotonin transporter 
SERT (Table 1).  
 
Table 1. 4-FA in-vitro uptake and release data  
Uptake a Release b Affinity c Ref 
DAT 
IC50/µM 
NET 
IC50/µM 
SERT 
IC50/µM 
DAT  
 
NET  SERT  DAT 
Ki/µM 
NET 
Ki/µM 
SERT  
Ki/µM 
 
-- -- ID50 = 
10 d 
4.10% d 1.16% d 2.98% d -- -- -- Magyar  and 
Knoll46 
ID50 = 
48.7 d 
-- ID50 = 
10 d 
-- -- -- -- -- -- Magyar et al.47 
0.270 0.356 2.352 -- -- -- -- -- -- Marona-
Lewicka  et al.42 
-- -- -- EC50/nM 
51.5 
EC50/nM 
28.0 
EC50/nM 
939 
-- -- -- Wee et al.7 
0.77 0.42 6.8 EC50/nM 
200 
EC50/nM 
37 
EC50/nM 
730 
-- -- -- Nagai et al.48 
9.5 10.3 94.83 -- -- -- -- -- -- Rosenauer  et 
al.49 
3.7 0.2 134 Yes e Yes e Yes e 11.0 13.5 32.1 Rickli et al.50 
0.091 0.0426 3.12 EC50/nM 
1400, Emax 
= 96% 
EC50/nM 
144, Emax 
= 145% 
EC50/nM 
11,100, 
Emax = 
99.5% 
33.6 18.5 75.8 Eshleman et 
al.51 
21 1.8 205 -- -- -- -- -- -- Zwartsen et al.52 
 
Additional in-vitro data  
Receptor binding profiles c: Ki (µM): 5-HT1A = 4.4; 5-HT2A = 11.3; 5-HT2C = 7.8; α1A > 4.9; α2A = 4.4; D1 > 
12; D2 > 20; D3 > 17; H1 > 13; TAAR1rat = 0.08; TAAR1mouse = 0.32; TAARhuman = 2.3; 5-HT2B receptor 
activation: EC50/µM = 11.4; activation efficacy = 49%.   
 
Rickli et 
al.50 
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Comparison with MDMA: Ki (µM): 5-HT1A = 12.2; 5-HT2A = 5.9; 5-HT2C > 13; α1A > 6; α2A = 15; D1 > 12; D2 
= 25; D3 > 17; H1 > 13; TA1rat = 0.37; TA1mouse = 2.4; TA1human = 14.6. 50 
 
Cytotoxicity: None detected under conditions used. f 
 
Release studies in mice using radiolabeled cardiac norepinephrine showed that 4-FA cause dose-
dependent release. At the 10 mg/kg level, observed release following amphetamine and d-
methamphetamine administration was comparable. g 
Benington 
and Morin 5 
Inhibition of monoamine oxidase (MAO): 40% inhibition at 1 mM. h Beregi et 
al.53 
Inhibition of phenethanolamine N-methyltransferase studied with pI50 = 3.01; comparison with 
tranylcypromine: pI50 = 4.05 i  
Fuller et 
al.54 
Binding to phenylalanyl-tRNA synthetase isolated from E. coli with Ki = 0.48 mM. Santi et al. 
55 
Investigation of MAO inhibition (MAOI) using rat brain mitochondria. I50 value for 4-FA = 16 µM 
compared to 1.9 µM for 4-chloroamphetamine. j 
Fuller et 
al.40 
Study with homologous initiating and non-initiating protein synthesis systems using rabbit reticulocyte 
lysates. 4-FA and amphetamine were observed to inhibit protein synthesis and aminoacylation under the 
conditions studied.  
Nowak and 
Munro56 
Investigation of MAOI using mitochondrial MAO obtained from whole rat brain homogenates. Fixed 
concentrations of 100 µM 14C-5-HT (MAO-A) and 14C-phenethylamine (MAO-B) were used as substrates. 
Ki/µM (4-FA) = 28 (MAO-A) and 240 (MAO-B), competitive inhibition. Comparison: Ki/µM 
(amphetamine) = 8.0 (MAO-A) and 475 (MAO-B).  
Fuller et 
al.57 
G-protein activation was not observed with 4-FA when using a [35S]GTPγS binding assay.   Nonaka et 
al.58 
In contrast to number cathinone derivatives, 4-FA and some other amphetamines, did not react with the 
tetrazolium-based WST-1 reagent when tested in the absence of SH-SY5Y neuroblastoma cells.  
den 
Hollander 
et al59 
4-FA (IC50 = 113 µM, reduction to 5% at 300 µM) decreased neuronal activity in multi-well 
microelectrode array recordings obtained from rat cortical neurons; reduction also observed with other 
substances, e.g. nicotine, GABA, diazepam, MK-801 and methoxetamine.  
 
Cytotoxicity: None detected under conditions used. l 
 
Hondebrink 
et al.60 
 
Binding and activity at rat, mouse, and human trace amine-associated receptor 1 (TAAR1).m Binding (Ki, 
µM) / activation (EC50, µM): 0.081 / 0.069 (Emax = 78%) (rat); 0.32 / 0.13 (Emax = 77%) (mouse); binding 
not determined / 3.5 (Emax = 67%) (human).  
 
Comparison with MDMA: 0.37 / 1.0 (Emax = 56%) (rat); 2.4 / 4.0 (Emax = 71%) (mouse); binding not 
determined / 35 (Emax = 26%) (human). 
 
Simmler et 
al.61 
a Ref42: Uptake inhibition studies carried out using rat whole synaptosomes. Ref 46, 47: rat brain homogenates obtained 
from CFY Sprague-Dawley rats following synaptosomal preparation procedure published by Snyder and Coyle for 
uptake inhibition studies.62 Concentrations of [3H]5-HT, [3H]DA and [3H]NE were 0.1 nmol/mL. Ref 50: HEK293-hDAT, 
HEK293-hNET, HEK293-hSERT; N-methyl-[3H]-nisoxetine and indatraline (NET), [3H]citalopram and indatraline 
(SERT), [3H]WIN35,428 and indatraline (DAT). Ref 42: whole brain minus cerebellum (male Sprague-Dawley rats) used 
for synaptosomal preparations; [3H]5-HT, [3H]DA and [3H]NE (10 nM). Ref 49: HEK293-hSERT, HEK293-hNET and 
HEK293-hDAT. Cells incubated with test compounds for 5 min before the tritiated substrates were added to incubation 
buffer: 0.03 μM [3H]5 HT and 0.05 μM [3H]MPP+. Ref51: HEK-hDAT, HEK-hNET and HEK-hSERT); [3H]DA (hDAT), [3H]5-
HT (hSERT) or [3H]NE (hNET) (20 nM final concentration). Ref52: HEK293-hSERT, HEK293-hNET and HEK293-hDAT; 
uptake of undisclosed fluorescence substrate, which was not subject to transporter-mediated release when tested 
using MDMA.    
 
b Ref 7: Synaptosomal preparations: rat caudate (for DA release) or whole brain minus cerebellum and caudate (for NE 
and 5-HT release); [3H]MPP+ as radioligand for DA and NE release, [3H]5-HT for 5-HT release measurements. Ref 50: 
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100 µM of test compound used. HEK293-hDAT, HEK293-hNET, HEK293-hSERT ([3H]DA, [3H]NE, [3H]5-HT). Ref 48: 
Synaptosomal preparations from male Sprague-Dawley rats: striatum for DA and cortex for 5-HT and NE; re-uptake 
assay initiated by addition of [3H]DA (63 nM), [3H]5-HT (125 nM), and [3H]NE (125 nM); reaction mixture was 
incubated at 37 °C for 5 min; for release assays: synaptosomes pre-loaded with [3H]DA, [3H]5-HT, and [3H]NE; release 
terminated after 5 min ([3H]DA) and 30 min ([3H]5-HT, and [3H]NE). Ref51: HEK-hDAT, HEK-hNET and HEK-hSERT) 
using a superfusion approach; cells preloaded with [3H]DA, [3H]5-HT or [3H]NE): normalized to maximal effect of 
methamphetamine (hDAT, hNET, and hSERT) or p-chloroamphetamine (some hSERT).  
 
c Ref 50: [3H]-8-OH-DPAT and indatraline (5-HT1A), [3H]ketanserin and spiperone (5-HT2A), [3H]mesulergine and 
mianserin (5-HT2C), [3H]prazosin and risperidone (α1 adrenergic receptor), [3H]rauwolscine and phentolamine (α2 
adrenergic receptor), [3H]SCH 23390 and butaclamol (DAD1), [3H]spiperone and spiperone (DAD2 and DAD3), 
[3H]pyrilamine and clozapine (H1) and [3H]-RO5166017 and RO5166017 (TA1). 5-HT2B activation: HEK293-h5-HT2B 
and FLIPR assay. Ref51: Binding [125I]RTI-55; HEK-hDAT, HEK-hNET and HEK-hSERT). 
 
d Ref 46: release from synaptosomes (rat cerebral cortex, hypothalamus and striatum) determined as a percentage value 
relative to control following the approach published by Ferris et al.63 Methamphetamine values: [3H]5-HT (5.23%), 
[3H]DA (8.85%) and [3H]NE (4.75%). 
 
e Ref 50: Monoamine release expressed as percent reduction of monoamine cell content compared with vehicle (0% = no 
release; 100% release all monoamines released from the cells). DAT: ~45%, NET: ~40%; SERT: ~50%. Essentially 
comparable with releasing activity of MDMA. 
 
f ToxiLight BioAssay (4 h, 37 °C, incubation with 100 µM test drug).  
 
g Ref  5: Injected DL-norepinephrine-7-3H retained by the heart tissue after drug treatment (tail vein injection of the 
male Swiss white mice); drugs administered subcutaneously after 1 h and mice were sacrificed after 3 h. At 10 mg/kg 
levels: 4-FA = 50%, amphetamine = 58% and d-methamphetamine = 57%. 
 
h Ref 53: Warburg’s technique was employed using tyramine as the substrate. Incubation was for 1 h at pH 7 and 37 °C. 
 
i Ref 54: Enzyme source: homogenate of whole rabbit adrenals; norepinephrine (40 µM) as substrate and measurement 
of epinephrine formation; enzyme transfer of methyl group using S-adenosyl-L-methionine (SAM) as co-factor.  
 
j Ref 40: [14C]Serotonin as substrate (100 µM); incubation with enzyme) for 20 min at 37 °C.  
 
k Ref 60:  Cortical neurons from cortex of Wistar rat pups at postnatal day 0-1;  cortical cultures consisted mainly of 
excitatory glutamatergic neurons, inhibitory GABAergic neurons and astrocytes.  
 
l Ref 60: Rat cortical neurons using the Neutral Red assay (30 min, 37 °C, incubation with 300 µM and 1 mM test drug). 
 
m Ref 61: Binding: HEK293 cells; [3H]RO5166017 as TAAR1 radioligand (not determined for human TAAR1); functional 
activity (cAMP measurements): endogenous TAAR1 ligands -PEA, p-tyramine, and tryptamine (Emax = 100%, 94% and 
91%).  
 
 
 
Table 2. 4-FA in-vivo assays 
Behaviour Neurochemistry / physiological 
responses / etc. 
Ref 
 
-- Toxicity studies in mice; see Section 5. In 
dogs and guinea pigs pressor activities 
were noted whereas depressing effects 
were observed in rabbits.   
Suter and 
Weston4 
-- Toxicity data from mice; see Section 5; 
hypertensive effects equivalent to 
amphetamine; anorectic effects 
Beregi et al.23 
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investigated in the rat at 5 mg/kg; 
locomotor effects in mice investigated at 
10 mg/kg. a 
-- Anorectic dose (mg/kg): rat = 3.5; dog = 
2.b Analgesia (mg/kg): mice = 10. b  
Anticonvulsant action (mg/kg): mice > 
20. b  
Vasopressive action. Rat: increase at 0.25 
and 0.5 mg/kg. b  
Beregi et al.53 
-- No significant impact on whole rat brain 
serotonin levels compared to saline. c   
Fuller et al.64 
Intraperitoneal administration of 5 mg/kg and 
10 mg/kg 4-FA in rats trained by the Sidman 
avoidance conditioning procedure. At the 10 
mg/kg dose, bar pressing was disrupted and 
resulted in death within 6–20 h.  
-- Beaton et al.65 
-- Temporary reduction of whole rat brain 
serotonin and 5-hydroxyindoleacetic 
acid levels and tryptophan hydroxylase 
activity (up to 24 h) whereas 4-chloro 
and 4-bromoamphetamine caused 
reductions for up to a week. d   
Fuller et al.40 and 
Gál 66 
-- 4-FA administration resulted in 
reduction of serotonin levels in 
brainstem and telencephalon when pre-
treated with iprindole. No changes 
observed 24 h without pre-treatment. 
Two weeks later, reductions were 
observed in both tissue extracts under 
both treatment conditions. e 
Sherman et al.67 
Unpublished data were mentioned that 4-FA 
did not show effects on the central nervous 
system. Details not reported.  
Administration of 14 mg/kg (i.p.) 
resulted in a 11.1% increase of 
tryptophan levels in rat brain whereas 
serotonin and 5-hydroxyindoleacetic 
acid levels did not change significantly. 
In comparison, a 10 mg/kg dose of 
amphetamine led to an increase of 96% 
with respect to tryptophan. Similarly, 
serotonin and 5-hydroxyindoleacetic 
acid levels remained unchanged. f 
Vial et al.68 
-- Anorectic properties of 4-FA comparable 
to d-amphetamine (ED50 = 2.5 vs. 1.8 
mg/kg) g 
Beregi and 
Duhault69 
-- 4-FA administration (100 µmol/kg) 
failed to produce serotonin depletion in 
rat brain sections 3 days after 
administration. h 
Harvey et al.70 
-- Intracerebroventricular injection of 4-FA 
(200 µg) resulted in increased levels of 
serum corticosterone, which pointed 
toward a mechanism without serotonin 
involvement since serotonergic 
neurotoxin administration did not 
impact on elevation. Dexamethasone 
pre-treatment (4 mg/kg) 4 h before 
McElroy et al.71 
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measurement prevented corticosterone 
elevation. i 
Drug discrimination: j Rats trained to 
discriminate fenfluramine (3 mg/kg) and 
saline. 4-FA (1.0–4.0 mg/kg) was found to 
substitute; 100% lever selection at 4 mg/kg.  
-- McElroy and 
Feldman44 
-- Tissue distribution following 4-[18F]A 
administration (i.v.) in mice was 
detected after 5 min (% does/organ:  
liver > kidneys > lungs > small intestines 
> brain > spleen) followed by a rapid 
decline at the 30 min and 60 min mark. k 
Shiue et al.41 
Drug discrimination: l 4-FA displayed (+)-
amphetamine-like discriminative stimulus 
effects; ED50: 0.23 mg/kg, 1.25 µmol/kg for 
training drug; 0.43 mg/kg, 2.11 µmol/kg for 4-
FA; no substitution observed for (+)-MBDB 
and MMAI. 
Microdialysis (rat striatum): l At 7 mg/kg 
(i.p.) of 4-FA, increase of extracellular DA 
levels (849%) 1 h after administration 
and non-significant decrease in DOPAC; 
when DA returned to baseline 3 h later, 
DOPAC and HVA concentrations still 
decreased. No effects of the 1.75 mg/kg 
dose. DA levels increases ~250% at 3.5 
mg/kg (at 90 and 120 min post-
injection). (+)-Amphetamine (2.0 mg/kg, 
i.p.) significantly increased dialysate DA 
levels from 30 to 120 min. DOPAC 
concentration not altered but HVA 
significantly decreased in DA dialysates 
at 1.5 h and 2 h following amphetamine 
injection. 
Marona-Lewicka  
et al.42 
Self-administration: m In rhesus monkeys, 4-
FA functioned as a positive reinforcer under 
fixed-ratio (FR) 25 schedule (biphasic dose-
response) and progressive-ratio (PR) 
conditions; reinforcing efficacy (PR schedule) 
lower than that of d-amphetamine. Potency 
(FR): 0.3 mg/kg; potency (PR): ED50 = 0.26 
µmol/kg/injection; d-amphetamine: ED50 = 
0.04 µmol/kg/injection. 
-- Wee et al.7 
Evaluation of anti-Parkinson effects: n 4-FA 
reported to significantly reduce haloperidol-
induced catalepsy in rats. 
 
Conditioned place preference: n 4-FA did not in 
behaviour associated with drug dependence.  
 
-- Nagel and 
Schmidt34, 35 
-- Cortical EEG and EMG: o 5 mg/kg (i.p.); 
wakefulness period: power spectral 
patterns revealed an increase in 
frequency range of 7.0−8.5 Hz and a 
decrease in that of 11.5−19.0 Hz for the 
first 7 h and decreased power spectra in 
the range 6.5−30.5 Hz for 8 h during 
non-REM sleep. 4-FA led to increased 
wakefulness for 7 h after administration; 
REM and non-REM sleep not detected in 
2 h to 6 h following administration. 
Uchiyama  et al.72 
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Locomotor activity: p Dialysate DA correlated 
positively with ambulation and stereotypy 
whereas dialysate 5-HT correlated positively 
with stereotypy but not ambulation.  
Microdialysis (rat nucleus accumbens): p 
Intravenous administration of 4-FA led 
to dose-related increases in dialysate: DA 
~ 12-fold and 5-HT ~15-fold.   
Baumann et al.43 
 
a Ref 23: male Sprague-Dawley rats; female NMRI mice. 
 
b Ref 53: Anorexia test. Rats: dose at which food intake was reduced by 50% for 2 h when drug administered 
orally one hour previously; dogs: oral minimum dose delaying food ingestion for 2 h. Analgesia (Haffner’s 
method in mice): intraperitoneal dose which inhibits reflex of biting the artery clip placed on tail by 50%. 
Anticonvulsant action: oral dose, which protects 50% of mice from tonic extension; bucco-occipital 
electroshocks were given (7.5 to 30 V lasting 1 s). Vasopressive action: blood pressure variation in pithed rat in 
mm Hg following intravenous administration.  
 
c Ref 64: Total radioactivity in the brain of male white Harlan rats was measured 20 min after i.p. injection of 5 
μmol DL-5-hydroxytryptophan-3-14C/kg.  
 
d Ref 40: male albino Wistar-derived rats; drugs administered intraperitoneally; drug levels in whole brain 
determined by methyl orange assay; tryptophan hydroxylase activity in whole brain homogenates assayed 
spectrofluorometrically; monoamine oxidase inhibition also determined, see Table 2. Serotonin and 5-
hydroxyindoleacetic acid levels in whole brain assayed spectrofluorometrically following derivatization.  
 
e Ref 67: Sprague-Dawley rats; intraventricular injection (600 µg) with and without iprindole (10 mg/kg, i.p. one 
hour before drug administration) treatment; cerebellum was removed to dissect into brainstem and 
telencephalon-cortical sections.  
 
f Ref 68: female Wistar rats; brain levels of tryptophan, serotonin and 5-hydroxyindoleacetic acid were 
determined following sacrifice after 60 min (amphetamine) and 90 min (4-FA), respectively.  
 
g Ref 69: male Long-Evans rats; inhibition of food consumption determined 2 h after oral administration of test 
drug. Values expressed as percentage of food consumed the preceding day.   
 
h Ref 70: Male albino rats (i.p. drug administration); brain sections B-7, B- and B-9 were isolated three days 
following administration and stained to determine abnormal staining and extent of neurotoxicity.  
 
i Ref 71: Male albino rats; trunk blood collected one hour after injection (i.c.v.); dexamethasone treatment 
(inhibition of pituitary ACTH secretion): 4-FA given 1 h before rats were sacrificed (i.p.) and either after 
dexamethasone (1 mg/kg i.p.) or 4 h after dexamethasone (4 mg/kg i.p.); chronic depletion of brain 5-HT 
induced by pre-treatment with p-chlorophenylalanine or 5,7-dihydroxytryptamine.  
 
j Ref 44: male albino rats. 
 
k Ref 41: Female CF-1 mice; lateral tail vein injection (0.3-1.5 mCi); tissues removed after 5, 30 and 60 min.   
 
l Ref 42: Male Sprague-Dawley rats; trained with (+)-amphetamine (1 mg/kg, 5.4 µmol/kg (i.p.), (+)-MBDB (1.75 
mg/kg, 7.18 µmol/kg (i.p.), MMAI (1.71 mg/kg, µmol/kg (i.p.). Microdialysis: dialysate collected every 30 min 
(striatum); i.p. injections of 4-FA HCI at 1.75, 3.5, and 7.0 mg/kg followed by determination of dopamine, 
DOPAC, and HVA; dialysates collected 1.5 h before and extended 3 h after injection of 4-FA or (+)-
amphetamine. 
 
m Ref 7: Seven male rhesus monkeys; FR schedule: baseline dose of cocaine = 0.03 mg/kg/injection; test drugs 
0.003–1.0 mg/kg; PR schedule: baseline dose of cocaine maintaining maximum injections = 0.1 or 0.3 
mg/kg/injection; test drug available at doses of 0.003–1.0 mg/kg. For FR schedule, mean dose that maintained 
responding at the peak of the biphasic curve was calculated for potency. For PR schedule, ED50 dose of dose-
response function obtained in individual monkey and averaged across monkeys for mean.  
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n Refs 34, 35: Sprague-Dawley rats; several fluorinated amphetamines and MDMA were included in these 
investigations. 1-(3,4-Difluorophenyl)-N-ethylpropan-2-amine was chosen as a representative example and it 
was claimed that 4-FA, amongst others, gave similar results. Haloperidol (i.p.) was administered at 0.5 mg/kg; 
quantitative assessment of descent latencies (in seconds) included comparisons between haloperidol and test 
drug. Conditioned place preference: daily dose of test drug was 5 mg/kg following FDA protocols; further 
details were not provided.   
 
o Ref 72: Male Sprague-Dawley rats (10 weeks old); electromyogram (EMG) and electroencephalogram (EEG) 
recorded for 48 h (24 h after saline treatment and 24 h following i.p. drug administration of 5 mg/kg); Cortical 
EEG and EMG signals were amplified, filtered (EEG, 0.5−35 Hz; EMG, 16–128 Hz) and recorded using 
‘SleepSign’ software.  
 
p Ref 43: Male Sprague-Dawley rats; microdialysis probe tips implanted in nucleus accumbens; locomotor 
activity: sensor ring lined with photobeams spaced 2.54 cm apart positioned in horizontal plane; activity 
monitored in 20 min bins, starting 60 min before intravenous drug injections and continuing for 120 min; 
ambulation and stereotypy quantified separately; ambulation is defined as the total distance travelled in the 
horizontal plane (measured in cm); rats received intravenous injection of 1 mg/kg of drug at time 0, followed 
by 3 mg/kg at 60 min and dialysate samples were analysed for 5-HT and DA.  
 
 
5. Toxicology 
Oral administration (white female Cartworth mice): LD0 = 15 mg/kg, LD50 = 25 mg/kg, 
LD100 = 50 mg/kg.
4 Intraperitoneal administration in mice: LD50 = 46.4 mg/kg
23, 73 and 46 
mg/kg, respectively.53 Oral administration (male CD Servier mice): LD50 = 150 mg/kg 
(comparison to d-amphetamine under identical conditions: 120 mg/kg).69 A cytolysis test 
with 4-FA did not lead to observations of cytotoxic effects under the conditions studied (4 h 
incubation at 37°C, drug concentration 100 μM).50 Similarly, another cell viability test 
studying the exposure of 4-FA to cortical neurons did not affect cell integrity under the 
investigated conditions (30 min incubation at 37°C, drug concentration 300 μM and 1 mM).60 
Data on the effects of 4-FA metabolites are not available.  
 
6. Adverse Reactions in Humans 
Tables 3 and 4 provide an overview of fatal and non-fatal intoxications obtained from the 
scientific literature and from reports received by the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA). Case report data reported in the scientific literature that 
unambiguously confirm a causal relationship between adverse 4-FA and presence in 
biofluids are limited to a relatively low number of cases. In cases where this information is 
available (e.g.74), sympathomimetic features, typically encountered with some 
amphetamine-type stimulants, have been observed. A recent study carried out in the 
Netherlands,29 which included a systematic survey of 4-FA users, who identified the main 
positive effect and the three most frequent adverse effects, confirmed that adverse effects of 
4-FA were consistent psychomotor/entactogen stimulant profile (Table 5).  
 
Dutch drug monitoring systems have received reports on increasing numbers of acute 
toxicity cases among young people attending large-scale events (median age 23 years). 
Between January and September 2016, 16% of reported acute toxic effects were associated 
with 4-FA, which compared to no reports between 2009 and 2011, less than 1% in 2012 and 
2013, 2% in 2014, and 11% in 2015. The Dutch Poisons Information Center was also 
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reported to receive increasing numbers of reports of 4-FA intoxications that increased from 
two in 2011 to 44 in 2015. Between January and September 2016, 33 reports were received, 
which included increasing number of reports of adverse drug reactions beyond those 
commonly observed with amphetamine-like substances (e.g. agitation, tachycardia, 
hypertension, and hyperthermia), such as pronounced cardiovascular toxicity, severe 
headache and cerebral hemorrhage but also deaths (analytical only available in some 
cases).75, 76 Following a risk assessment carried out by the Dutch Centre for the Assessment 
and Monitoring of new drugs (CAM), it was concluded that the risk to individual health was 
small to moderate but with high risk for acute toxicity especially in subpopulations 
associated with clubbing. The risk to public health was deemed moderate to large based on 
rising trends in use number of health incidents. The overall risk score of 4-FA was considered 
high.38  
 
Table 3. Fatal case reports associated with 4-FA published in scientific literature.  
Year Cases Patient, 
age 
Context/clinically related comments  Notes Reference 
2012 1 F, 44 HIV-positive, 18 years history of drug 
dependence undergoing methadone 
treatment. Death considered due to high 
level of methadone in combination with 
4-FA and amphetamine. 
Whole blood analysis: 4-FA 
0.58 mg/kg; amphetamine 
0.30 mg/kg; diazepam 0.029 
mg/kg; oxazepam 0.043 
mg/kg, methadone 0.65 
mg/kg.  
Johansen and 
Hansen77 
2013 1 Not 
reported 
Not reported.  Detection of 4-FA in one 
post-mortem blood sample. 
Rosano et 
al.78 
2017 2 Not 
reported 
See also Table 4 (Nugteren-Van 
Lonkhuyzen et al.75) Analytical 
confirmation (in blood/urine) in 4 cases. 
Three of these patients ingested one 4-
FA capsule (plus cannabis in 1 patient) 
and developed severe headache and 
cerebral hemorrhage. One of these 
patients died. The fourth patient died 
due to extensive bowel ischemia 
following chronic 4-FA use. In this 
patient and in one of the patients with 
cerebral hemorrhage, pronounced 
cardiovascular toxicity was also 
observed. 
 
See also Wijers et al.76 
Analytical confirmation 
(blood/urine; details not 
reported). 
Nugteren-Van 
Lonkhuyzen 
et al.75 
 
 
 
Table 4. Non-fatal case reports associated with detection of 4-FA reported in the scientific literature.a  
Yearb Cases Patient, 
age 
Context/clinically related comments 
(examples) 
Notes Reference 
2012 14 12 x M, 
19-38; 
2 x F, 17 
and 21 
Case history details not reported. Amphetamine 
also detected in most cases; whole blood 0.049 
mg/kg – 0.70 mg/kg; in nine cases, additional 
drugs were detected, such as several 
benzodiazepines, tetrahydrocannabinol (THC), 
ketamine, 4-methylamphetamine and lidocaine.  
Cases observed 
between 2009 – 
2011. One rape case 
and 13 DUID cases. 
Whole 4-FA blood 
concentrations in 
DUID cases between 
Johansen and 
Hansen77 
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0.006 – 0.43 mg/kg 
(mean 0.087 mg/kg, 
median 0.021 
mg/kg).  
 
2012 2 Not 
reported 
Case 1: police traffic check and medical 
examination indicative of sympathomimetic drug 
use: pupils dilated and delayed contraction in 
response to light; fingertips trembling; Romberg 
test showed tremor and swaying; restless 
behavior. Case 2: symptoms associated with 
psychostimulants, such as slow pupil light reflex, 
tremor and restlessness. 
DUID cases. 4-FA 
serum 
concentrations 350 
ng/mL and 475 
ng/mL.  
Röhrich et 
al.74 
2012 14 Not 
reported 
Not reported.  4-FA was detected in 
12 cases subjected 
to hair analysis. 
Rust et al.79 
2013 14 Not 
reported 
Not reported. Urine drug screening of authentic 
samples obtained from ‘addiction treatment 
clinics’ during one year in Sweden.  
In combination with 
4-FMC (3), 3-FMC 
(1) and MDPV (1). 
Total number of 
urine samples: 1335. 
Al-Saffar et 
al.80 
2013 2 Not 
reported 
Not reported. In 2010, 103 cases received from 
patients presenting at emergency departments 
across Sweden. 
4-FA detection 
reported in 2 cases. 
Helander et 
al.81 
2013 5 Not 
reported 
Not reported. Analysis of 1335 DUID cases. 4-FA detected in 
whole blood and 
considered below 
the legal limit.  
Pedersen et 
al.82 
2014 1 M, 18 Abrupt onset of nausea, vomiting, shortness of 
breath and chest tightness 5 h after drug 
consumption; received intramuscular naltrexone 
two days prior to admission as part of opioid 
addiction treatment program; fluoxetine and 
trazodone were also taken. ‘Reverse takotsubo 
cardiomyopathy’: cardiogenic shock developed 
requiring invasive management and life support. 
Acute cardiomyopathy caused by 4-FA 
catecholamine- induced myocarditis and/or 
small vessel myocardial ischemia was suggested. 
 
It has been suggested that the medication used 
during treatment might have contributed to 
triggering the Takotsubo syndrome.83 
4-FA urine and 
serum levels 64,000 
ng/mL and 118 
ng/mL. Also 
detected in urine: 
naproxen, 
fluoxetine, 
trazodone, 
naltrexone, nicotine, 
and cotinine in 
urine; in serum: 4-
FA, naproxen, 
trazodone, and 
cotinine. 
Al-Abri et 
al.84 
2015 1 M, 27 Patient with history of polysubstance 
dependence; agitated with non-sensible speech, 
diaphoresis, dilated pupils, and hyperreflexia 
without clonus. Vital signs included: heart rate 
156 beats/min and rectal temperature 41.4 °C; 
treatment: dextrose (50 g, i.v.), midazolam 
(multiple boluses, i.v., 28 mg in total), and 
submerged in ice water.  
Urine tests with 
EMIT positive for 
amphetamines and 
PCP; qualitative 
serum and urine 
analysis confirmed 
presence of 4-FA. 
 
Poklis et al.85:  
Serum 23 h post-
admission (ng/mL): 
4-FA 1,400; PCP 4.7; 
diazepam 170; 
Laskowski et 
al.86 
 
Quantiative 
data reported 
by Poklis et 
al.85 
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nordiazepam 83 
(treatment-related). 
Urine 4 h post-
admission (ng/mL): 
4-FA 285,000; PCP 
107 (diazepam and 
metabolite not 
detected). Urine 23 h 
post-admission 
(ng/mL): 4-FA 
124,000; PCP 12; 
diazepam 420; 
nordiazepam 2,000. 
 
2015 1 M, 35 Routine traffic control; slow coordination, 
deficiency in concentration, washed-out 
pronunciation, agitation, restlessness, dry mouth, 
eyes reddened, and glassy, and pupil 
abnormalities (slow reaction to light, enlarged 
pupils). Orders had to be repeated multiple times 
and the man could not follow long sentences.  
Blood sample taken 
1 h and 55 min 
afterwards: THC 0.9 
ng/mL; 11-OH-THC 
< 0.8 ng/mL; THC-
COOH 6.8 ng/mL; 4-
FA 90.0 ng mL. 
Maas et al.87 
2015 4 Not 
reported 
Tachycardia, headache, dizziness, restlessness, 
visual disturbances, tremors, agitation, 
tachypnea, confusion, nausea, vomiting, 
abdominal pain, dysphagia, neck pain, feeling of 
fainting. 
Reported to the 
Dutch Poisons 
Information Centre 
in 2013. 
Hondebrink 
et al.88 
2016 1 Not 
reported 
Retrospective analysis of 200 urine samples 
collected consecutively between October 2013 
and April 2014 from 82 different opioid-
dependent patients.  
4-FA, amphetamine, 
alprazolam, THC-
COOH, and zolpidem 
detected. 
Heikaman et 
al.30 
 
Unclear if 
same case 
mentioned in  
Sundström et 
al.89 (below). 
2016 1 Not 
reported 
Details not reported.  4-FA detected in one out of 
34 irregular attendees of drug treatment centre.   
4-FA detected, no 
further details.  
Sundström et 
al.89  
2017 3 M, 21 
F, 19 
M, 22 
 
Self-reported use of 4-FA. One patient exhibited 
rhabdomyolysis; hyperthermia, hypertension 
and tachycardia were commonly observed; one 
patient consumed 14 tablets as a suicide attempt. 
Analytical 
confirmation not 
available.  
Knippels et 
al.90 
2017 20 Not 
reported 
See also Table 3 (Lonkhuyzen et al.75). Between 
January-September 2016, the Dutch Poisons 
Information Center was consulted about thirty-
six 4-FA exposures; follow-up performed in 22 
cases with either physician and/or patient. 
observed symptoms included restlessness 
(77%), headache (68%), anxiety (59%), 
tachycardia (59%), hypertension (50%), 
confusion, tachypnea, chest pain (all 41%), 
seizures and coma (both 14%). More pronounced 
cardiovascular toxicity observed in 11 cases (2 
analytically confirmed). These included 
conduction abnormalities (prolonged QTc or QRS 
interval, right bundle branch block), acute heart 
failure and arrhythmias (including bigeminy). 
One of these patients developed  inverted 
Analytical 
confirmation in 6 
cases (blood/urine; 
details not reported) 
Nugteren-Van 
Lonkhuyzen 
et al.75 
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Takotsubo cardiomyopathy following intake of 
two 4-FA capsules with a 30-minute interval 
(plus 5 units of alcohol, exposures not analytically 
confirmed). Analytical confirmation (in 
blood/urine) in 4 cases. Three of these patients 
ingested one 4-FA capsule (plus cannabis in 1 
patient) and developed severe headache and 
cerebral hemorrhage. One of these patients died. 
The fourth patient died due to extensive bowel 
ischemia following chronic 4-FA use. In this 
patient and in one of the patients with cerebral 
hemorrhage, pronounced cardiovascular toxicity 
was also observed.  
 
See also Wijers et al.76 
2017 4 
 
Not 
reported 
Analysis of 558 blood samples and 199 oral fluid 
samples obtained during traffic controls in 
Belgium between January and August 2015. In 
one case, blood-red eyes, dry mouth, trembling 
arms and legs but also equanimity was observed 
(amphetamine and THC-COOH also detected). 
4-FA detected in 3 
blood samples and 1 
oral fluid sample. All 
samples also 
contained other 
drugs. 
Wille et al.91 
2017 1 F, 18 Presented to emergency department (ED) after 
drinking two capfuls of “Molly’s Mosquito cap”; 
also reportedly insufflated 110 mg 
methylphenidate and ingested 800 mg modafinil. 
Experienced headache, nausea, vomiting, 
lightheadedness, and diaphoresis. On arrival to 
emergency department, only complaint was 
anxiety; clinical feature features were associated 
with acute dilated cardiomyopathy and 
myocardial injury. 
4-FA detected in 
urine at 37,000 
ng/mL. 
Concentrations of 
methylphenidate 
and modafinil not 
reported. 
Wolf et al.92 
a The EMCDDA also received reports about positive identifications of 4-FA in biofluids although case level data are not 
reported, see Table 7. b Year of publication with allocation of volume and page number; some cases have been 
encountered before that.  
 
 
Table 5. Reported positive and adverse effects of 4-FA, adapted from Linsen et al.a,29  
Effects n % 95% CI 
Positive       
Stimulatory 145 58.2 51.4–64.3 
Euphoria 69 27.9 22.1–33.3 
Empathic 24 9.6 6.0–13.3 
Sedative 11 4.3 1.1–5.6 
    
Adverse       
Difficulty falling asleep 133 53.4 47.4–59.0 
Dry mouth 109 43.8 37.4–50.2 
Jaw tension/cramp 106 42.6 36.2–49.0 
Elevated heartbeat 92 36.9 30.9–43.4 
Sweating/high body temperature 83 33.3 27.7–39.4 
Lowered mood in the days after use 49 19.7 14.9–24.5 
Muscle weakness in days after use 46 18.5 13.7–23.3 
Nausea 17 4.8 3.6–10.0 
The drug had no effect 16 6.4 3.6–9.6 
Tachycardia 29 11.6 8.0–15.7 
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Headache 21 8.4 5.2–12.4 
Loss of memory (while intoxicated) 17 6.8 4.0–10.4 
Unpleasant hallucinations 3 1.2 0.0–2.8 
Difficulty breathing 2 0.8 0.0–2.0 
Tolerance (higher dose needed after first use) 16 6.4 3.6–9.6 
Other 6 2.4 1.0–4.6 
a Multiple answers were possible for adverse effects; CI = confidence interval. Users of 4-FA have 
identified pro-social effects similar to MDMA, which was not associated with effects induced by 
amphetamine.   
 
7. Dependence Potential 
A. Animal Studies 
As shown in Table 2, self-administration studies in rhesus monkeys indicated that 4-
FA functioned as a positive reinforcer under fixed-ratio (FR) 25 schedule (biphasic 
dose-response) and progressive-ratio (PR) conditions. The reinforcing efficacy (PR 
schedule) was lower than that of d-amphetamine and it was hypothesized that the 5-
HT releasing effects of 4-FA might have negatively impacted on the potency as a 
reinforcer compared to d-amphetamine. Correspondingly, it was suggested that a 
DA/5-HT ratio might serve as a potential predictor. Taking into account the EC50 
values obtained from rat brain synaptosome release assays, the DA/5-HT ratio 
obtained for 4-FA was 0.05 compared to 0.004 for d-amphetamine, which reflected 
the higher 5-HT releasing potency of 4-FA.7 An example was found in the patent 
literature where it was claimed that 4-FA did not display signs of dependence 
potential based on experiments that assessed conditioned place preference (Sprague-
Dawley rats).34, 35 Further studies seem warranted to determine the extent of 
dependence potential in animals.  
B. Human Studies 
Data from clinical studies in humans are not available.  
 
8. Abuse Potential 
A. Animal Studies 
As shown in Tables 2 and 3 and Section 4, limited information is available. From the 
available data it appears that 4-FA shows classic features associated with other 
psychomotor stimulants. The available information related to amphetamine-like 
properties suggests that abuse liability might be extendable to humans. Further 
studies seem warranted to clarify the similarities and differences that might exist 
between 4-FA and amphetamine and other amphetamine-type substances.  
B. Human Studies 
Data from clinical studies in humans are not available.  
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9. Therapeutic Applications and Extent of Therapeutic Use and 
Epidemiology of Medical Use 
Not applicable. 
 
10. Listing on the WHO Model List of Essential Medicines 
4-FA is not listed on the WHO Model List of Essential Medicines (20th List) or the WHO 
Model List of Essential Medicines for Children (6th List). 
 
11. Marketing Authorizations (as a Medicinal Product) 
4-FA was never marketed as a medicinal product.   
 
12. Industrial Use 
4-FA has no recorded industrial use. 
 
13. Non-Medical Use, Abuse and Dependence 
Use of 4-FA appears to be limited to recreational substance users rather than the general 
population. The mode of use may involve the combinational use (intentionally or 
unintentionally) of other drugs and users may be unaware of the exact dose or compound 
being ingested (by whatever route). Dependence-producing properties in humans have not 
been studied. The appearance of 4-FA in Europe has been observed since at least 2007. Over 
the years, it has been found in products sold as ‘ecstasy’/MDMA tablets, amphetamine 
powder but also as adulterants present in other illicit controlled substances.28, 29, 45, 88, 93-95 
However, 4-FA is also available in its own right, either from on-line or off-line retailers and 
specifically sought after.38, 96  
 
   Also see Annex 1: Report on WHO questionnaire for review of psychoactive substances. 
 
14. Nature and Magnitude of Public Health Problems Related to Misuse, 
Abuse and Dependence 
Surveys that systematically assess the prevalence of 4-FA use within the general population 
are not available. Research carried out in the Netherlands suggest that 4-FA, which originally 
appeared as one of many new psychoactive substances (NPS) (e.g. as an adulterant or as an 
alternative to reduced availability of substances such as MDMA) has established itself as a 
substance of choice in a subpopulation of recreational substance users, especially those who 
might prefer using this substance in a social context.29, 38, 88 In The Netherlands, 4-FA has 
become increasingly popular amongst users of new psychoactive substances who are 
associated with participation at music festivals and clubs, which led to increased numbers of 
incidents with adverse effects and high toxicity, thus, potentially leading to an in increased 
risk to public health.38 Further studies are indicated to investigate the prevalence of use in 
other countries. Some detections of 4-FA in biofluids related to roadside testing have been 
described (Table 3). Dependence-producing properties in humans have not been studied. 
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Also see Annex 1: Report on WHO questionnaire for review of psychoactive substances. 
      
15. Licit Production, Consumption and International Trade 
No data available.  
 
16. Illicit Manufacture and Traffic and Related Information 
Information provided to Europol and EMCDDA by European Member States, Turkey and 
Norway is summarized in Table 6.  
 
Table 6. Information available on the EMCDDA’s European database on new drugs (EDND). The European Union Early 
Warning System, the Reitox National Focal Points in the EU Member States, Turkey and Norway, as well as the Europol 
National Units and their networks, provided data. a 
Information provided to EMCDDA 
Seizures 2008: 
• Belgium – 2 seizures of powder. 
• Denmark – 2 seizures; 1 sample seized (4 g) containing 1% amphetamine. 
• Netherlands – 4 collected samples of powder; 1 collected sample of capsule; 1 collected sample of liquid; 3 
seizures totalizing 212 g of powder and 1 seizure of liquid containing also 2C-B and BZP. 
Seizures 2009 (January – June) plus update from 9th Annual EWS meeting, 4-5 June 2009, Lisbon (A. Gallegos and R. 
Sedefov): 
 
• Austria – 2 seizures of powder totaling 707 g and 4 collected samples of powder. 
• Belgium – 6 seizures of 33.9 g powder; 1 seizure of 49.79 g of paste/sticky powder and 1 seizure of tablets. 
• Croatia: 4 seizure of white powder also containing amphetamine traces, caffeine, mannitol and creatine. 
• Denmark – 5 seizures; one seizure of 4 g white powder that also contained 1% amphetamine. 
• Estonia – 1 seizure of 0.32 g powder. 
• Finland – 1 seizure of 12 tablets (Forensic Laboratory) and 2 seizures of powder/capsule, 5g/3units (Customs) 
• France – 8 seizures of powder, 3115 g 
• Germany – seizure between November 2008 and June 2009: in one case, 60 kg of amphetamine were seized, 14 
of which were a mixture of amphetamine and 4-FA; two seizures of a ‘few grams’ of powder and one seizure of 1 
kg.    
• Hungary – 2 seizures of powder, 2.5 g (powder in 36 capsules); 1 collected sample of 638.2 g powder; 4 seizures 
of 211 tablets (from 2008), one seizure of 700 g homogenous powder. 
• Netherlands – From DIMS: 60 collected samples of powder, 6 collected samples of tablets and 1 collected sample 
of liquid from NFI: 1 seizure of powder > 340 kg; 98 seizures of powder, > 100 kg, 98 seizures of powder > 100 
kg in combination with amphetamine. 
• Slovakia – 1 seizure of 16 mg powder. 
• Sweden – 105 seizures of 6174 g powder; 7 seizures of 21 mL liquid; 24 biological samples of urine; 71 
biological samples of blood and 57 seizures of 1460.4 g powder. 
• United Kingdom – 2 seizures of 0.9 mL liquid; 102 seizures (93 kg powder); 4 seizures (6.67 kg powder); 6 
seizures of paste (6.355 kg); 1 seizure of 300 g powder; 1 seizure of 7.627 kg paste containing also amphetamine. 
UK National Focal Point also reported a seizure of 371 mg of a pale pink powder in Guernsey.  
Seizures 2010: 
 
• Belgium – 1 seizure of 112.5 tablets containing also caffeine and piperonal; 1 seizure of 3.18 g powder 
containing also caffeine and amphetamine; 3 biological samples of urine. 
• Denmark – 13 seizures. 
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• Finland – 3 seizures of 5g powder; 1 biological sample of blood; 13 seizures of 46 g powder and 1 seizure of 2 
tablets (last two, both reported as 3-FA or 4-FA). 
• France – 4 seizures of 340 g liquid; 7 seizures of tablets. 
• Hungary –10 seizures of 35 g powder and 7 seizures of 14 tablets (reported as fluoramphetamine). 
• Netherlands – 13 seizures: 2775 tablets and 65 g powder (from NFI). 
• Norway – 8 seizures of 106 g powder. 
• Poland – 1 seizure of 10 capsules; 1 seizure of 550 tablets containing piperonal and caffeine. 
• Slovenia – 5 seizures of 9.21 g white powder, most of the samples containing caffeine. 
• United Kingdom – From a variety of forensic providers. Key Forensics: 3 seizures of powder, 157.7 g; 1 seizure of 
powder, 23.5 g in an amphetamine sample. From LGC Forensics: 6 seizures of powder, 136.3 g; 13 seizures of 
powder, 520 g. From FSNI: 1 seizure of 16.76 g powder containing traces of mephedrone; 1 seizure of 102 g white 
powder. From FSS: 3 seizures of liquid, 1.6 mL; 152 seizures of powder, 46.4 kg; 1 seizure of 5 tablets. From 
Scotland: 9 seizures of powder, 529.5 g. From Key Scientifics: 3 seizures of powder, 14.46 g; 1 seizure of 2 
tablets, 0.46 g; 3 seizures of powder, 5.73 g. 
Seizures 2011: 
 
• Austria –1 seizure of 9.4 g of powder. 
• Bulgaria – 3 seizures of 5.60 g of powder 
• Denmark – 5 (19)* seizures of 442.2 g of powder (*The number in brackets is the total number of individual 
exhibits in all seizures). 
• Finland – 38 seizures of 198 g of powder; 4 seizures of 20 tablets/blotters; 7 seizures of 82 g of powder; 2 
biological samples of blood (all reported as 2-, 3- or 4-FA). 
• France – 17 seizures of tablets. 
• Hungary – 18 seizures of 15 g of powder, 60 seizures of 3235 tablets; 27 seizures of 26 g powder also containing 
amphetamine; 1 seizure of 3 tablets also containing 2C-D; 462 biological samples. 
• Italy – 1 seizure of 1.18 g of tablets; 2 seizures of powder (one seizure also contained MDPV, 4-MEC, lidocaine 
or procaine and the other also contained mephedrone and MDPV, lidocaine and propanamide were also 
identified). 
• Netherlands – 7 seizures of 279 tablets and 16 g powder (from NFI); 61 collected samples of powder (from 
DIMS); 9 collected samples of tablets (from DIMS); 3 collected samples of liquid (from DIMS); 1 collected 
sample of capsules (from DIMS). 
• Norway – 3 seizures of 517 g of powder. 
• Spain – 1 seizure of powder. 
• United Kingdom – From FSNI: 1 seizure of 2.05g of powder; from FSS: 13 seizures of 400.1 g powder. 
Seizures 2012: 
 
• Austria – 1 seized powder sample. 
• Belgium – 1 kg white powder seized by customs at airport, package sent from China. 
• Denmark – 3 cases of seized powder, 9.5 g. 
• Spain – Seizure of 7760 tablets and 15 tablets where 4-FA was present in combination with other substances; 
seizure of 210 g powder. 
• Finland – Customs seizures of 243.8 g powder (53 cases), 18 tablets/blotter and 28.8 g ‘other’. Police seizure 
of 28 g powder and 10 cases of biological analyses with positive identification. Note: not clear what 
positional isomer might have been identified.  
• France – seizures of tablets (5 cases) and two liquids (customs); police seizure of 100 tablets. 
• Hungary – seizures of 421 tablets (13 cases), 2 g powder (2 cases); presence of additional substances: 7 g of 
powder (4-FA + amphetamine, 4 cases), 38 g of powder (4-FA + MDPV, 1 case), 33 tablets (4-FA + 
methoxetamine, 1 case), 30 tablets (4-FA + 4-MEC + methylone, 1 case); 43 samples of biological origin 
tested positive for 4-FA but details not reported.   
• Netherlands – seizure of 1060.2 g (27 cases), 7 tablets and 11 tablets (4-FA + PMMA + 3,4-
dimethoxymethamphetamine).    
• Norway – seizure of materials in three cases and positive identification in one biofluids sample. 
• Poland: 1 g powder and 2.99 g powder also containing amphetamine and caffeine.   
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• Slovakia – seizure of 367 g powder (see also Reitox National Focal Point Slovakia, below). 
• Slovenia – 1 powdered sample (1.3 g). 
• United Kingdom – Seizures of 1010 g powder (18 cases), 1488.57 mL liquid (3 cases), 1 tablet and 1 ‘other’ 
(6.34 g). 
 
Seizures 2013: 
 
• Denmark – 2 cases of collected powder (1.9 g) 
• Finland – Powder (141.6 g, 34 cases); positional isomer not specified. 
• France – seizure of tablets (6378 g, 37 cases), liquid (9312 g, 40 cases), and 97 g powder (8 cases).  
• Greece – seizure of 2.4 g powder 
• Italy – seizure of 1.69 g powder containing 4-FA + 4-MEC + methedrone (bk-PMMA) + methylone + 5-MeO-
MIPT + 5-MeO-DALT. 
• Latvia – seizure of 49.42 g powder 
• Poland – seizure of 796.66 g powder (64 cases) 
• Spain – 50 g powder (12 cases) and 11 g powder (18 cases) containing additional substances. 
 
Information provided to Europol 
Seizures 2009 (January – June) plus update from 9th Annual EWS meeting, 4-5 June 2009, Lisbon (A. Gallegos and R. 
Sedefov) and newsletter related to Europol’s SYNERGY project97  
  
• Sweden: Two seizures of 700 g and 340 g.  
• Netherlands: found at two illegal amphetamine laboratories. 
• From SYNERGY newsletter: ‘A total of 19 member states had replied to Europol’s request for information, 
with four member states (Finland, Germany, the Netherlands and the United Kingdom) reporting seizures 
of the substance, both in powder and tablet form. Additionally, insofar not yet officially provided, the Slovak 
Republic has also forensically identified this substance amongst submitted seizures. Equally, reports 
submitted to the EMCDDA from the NFP’s reveal that seizures of this substance have taken place in Belgium, 
Croatia, Denmark, Estonia, France and Hungary.’ 
 
‘In fact, the Dutch National Crime Squad reported that this substance was increasingly emerging on the 
national users market. Also, two production sites had been dismantled, with one in January 2009 where both 
this substance and its precursor chemical were seized; the other took place in February 2009, where traces 
of both this substance and amphetamine were found. Besides, one additional seizure totalling 169 kg of the 
substance was made in January 2009.’  
 
Reitox National Focal Point Slovakia 
 
• Rented premises were used for 4-FA manufacturing, packing and distribution. Mixing equipment and 
facilities for pills processing were encountered, including 367 g powdered 4-FA. 
 
a Some of the data reported to Europol and EMCDDA may overlap. Data were drawn from bi-annual data gathering 
(EU EWS progress and final reports) and from individual Reporting forms submitted on an ad hoc basis to EMCCDA. 
Positive identifications of 4-FA in various biofluids have also been reported but further details are not available. 
 
17. Current International Controls and Their Impact 
4-FA is not controlled under the 1961, 1971 or 1988 United Nations Conventions. 
 
18. Current and Past National Controls 
The EMCDDA’s European database on new drugs (EDND) lists that the following countries 
have taken legislative measures to control 4-FA: Belgium, Czech Republic, Denmark, 
39th ECDD (2017) Agenda item 4.3   4-FA  
 
 
 
Page 26 of 46 
Finland, France, Germany, Hungary, Italy, Latvia, Lithuania, Norway, Poland, Portugal, 
Slovakia, Slovenia, Sweden, Turkey, United Kingdom. 4-FA is not a controlled Substance 
in Greece. Confirmation from all Reitox European National Focal Points, however, might be 
needed to obtain an update.  Also see Annex 1: Report on WHO questionnaire for review of 
psychoactive substances. 
 
19. Other Medical and Scientific Matters Relevant for a Recommendation on 
the Scheduling of the Substance 
Not applicable. 
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Annex 1: Report on WHO Questionnaire for Review of Psychoactive 
Substances for the 39th ECDD: Evaluation of 4-FA 
 
Please refer to separate Annex 1 document published on ECDD website 
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Annex 2: Studies associated with the detection and chemical analysis 
of 4-fluoroamphetamine (amongst other substances) published in the 
scientific literature. 
 
Techniques a Comment Reference 
Thermal methods Characterization of 4-FA HCl polymorphism. Marthi et al.1 
1H-NMR Characterizations of compound including use chiral Eu-
shift reagents. 
Podányi2 
XRD Characterization of crystal structure properties of 
compound. 
Simon et al.3 
GC-MS Metabolism study in rats following administration of 
para-fluoro-deprenyl.  
Lajtha et al.4 
GC-MS, IR, NMR Characterization of seized compounds. Rösner et al.5 
GC-MS, LC, LC-MS Characterization of collected compounds. Kikura-Hanajiri et 
al.6 
LC-FL, LC-TOF-MS Characterization of collected compounds. Min et al.7, 8 
GC-MS, LC-DAD Characterization of collected compounds. Takahashi et al.9 
GC-(EI/CI)-MS(/MS) Characterization of seized compounds. Westphal et al.10 
LC-FL, LC-ESI-TOF-MS Characterization of collected compounds. Inagaki et al.11 
PS-MS, CE-MS, CZE-UV Method development. Jhang et al.12 
LC-TOF-MS Detection in whole blood samples related to casework.  Johansen and 
Hansen13 
Various approaches to 
ionization and MS 
Method development. Lee et al.14 
1H-NMR and UV 4-FA obtained from synthesis.  Lichtenberger 15 
GC-MS Employment of chiral derivatization reagent. Mohr et al.16 
Immunoassays Evaluation of cross-reactivities to EMIT assays. Nakanishi et al.17 
GC-MS, LC-Q-TOF-MS, 
NMR 
Characterization of seized compounds. Reitzel et al.18 
Immunoanalysis, GC-MS Detection biofluids. Röhrich et al.19 
LC-Q-trap-MS/MS Detection in hair samples. Rust et al.20 
LC-TOF-MS Characterization of collected compounds. Shanks et al.21 
UHPLC-QqQ-MS/MS Detection in oral fluid. Strano-Rossi et 
al.22 
PTR-MS Method development.  Sulzer et al.23 
LC-QqQ-MS/MS Detection in authentic urine samples. Al-Saffar et al.24 
CE-LIF, CE-UV, MEKC-
UV 
Method development for saliva analysis. Chen et al.25 
LC-QqQ-MS/MS Analyses of biofluids. Helander et al.26 
GC-MS Method development and application to waste water 
analysis. 
Mwenesongole  et 
al.27 
GC-MS, LC-MS, NMR Synthesis and characterization of regioisomers. Nakazono  et al.28 
LC-Q-TOF-MS Method development in whole blood and application to 
casework. 
Pedersen et al.29 
Immunoanalysis Cross-reactivity studies. Petrie et al.30 
39th ECDD (2017) Agenda item 4.3   4-FA  
 
 
 
Page 37 of 46 
Colour spot test Method development using a spectrophotometric 
reagent. 
Philp et al.31 
LC-TOF-MS Method development and application to postmortem 
blood samples. 
Roman et al.32 
UPLC-QqQ-MS, LC-Q-
TOF-MS 
Method development in blood matrix for application to 
casework. 
Rosano et al.33 
LC-DAD, LC-Q-MS Method development and application to collected 
samples combined with in vitro pharmacology assays. 
Rosenauer et al.34 
Melting point, 1H-NMR, 
GC-MS, ATR-FTIR 
Characterization of reference material. SWGDRUG35 
GC-MS, LC-DAD, LC-Q-
TOF-MS, NMR 
Detection of seized compounds. Zuba et al.36 
HS-SRI-TOF-MS Method development. Acton et al.37 
LC-Q-TOF-MS/MS, LC-
Q-ion trap-MS/MS 
Detection in serum and urine. Al-Abri et al.38 
LC-UV Biocatalytic synthesis of chiral species. Au et al.39 
LC-DAD Method development for chiral separation.  Geryk et al.40 
TLC, GC-MS Analysis of submitted samples to drug checking service. Giné et al.41 
GC-FID, NMR Biocatalytic synthesis of chiral species. Green et al.42 
Immunoanalysis, GC-MS Method development and chemical derivatizations.  Holler et al.43 
LC-Q-TOF-MS Method development for urine analysis.  Paul et al.44 
LC-QqQ-MS/MS Method development for hair analysis and application to 
authentic specimens. 
Strano-Rossi et 
al.45 
LC-QqQ-MS/MS Method development for urine analysis and application 
to authentic specimens. 
Tang et al.46 
LC-UV Chiral analysis of products obtained from Internet 
retailers. 
Taschwer et al.47 
LC-DAD Method development for chiral separation. Geryk et al.48 
TLC, GC-NPD, GC-MS Identification of submitted samples. Hondebrink et  al.49 
LC-DAD Method development for chiral separation. Kalíková  et al.50 
EMIT, LC-QqQ-MS/MS Detection in serum and urine. Laskowski et al.51 
GC-MS, LC-QqQ-MS/MS Detection in serum. Maas et al.52 
GC-FID Biocatalytic synthesis of chiral species. Mutti et al. 53 
LC-QqQ-MS/MS Method development in whole blood. Odoardi et al.54 
LC-QqQ-MS/MS Method development for wastewater and river water 
analysis. 
Senta et al.55 
LC-QqQ-MS/MS Method development for blood analysis. Adamowicz et al.56 
LC, SFC, CEC, Method development for chiral separation. Albals et al.57 
Raman Differentiation between regioisomers. Chen et al.58 
Presumptive colour tests Use of commercially available reagents. Cuypers et al.59 
SFC Method development for chiral separation Geryk et al.60 
GC-FID Biocatalytic synthesis of chiral species. Gomm et al.61 
LC-Q-TOF-MS Detection in pooled urine sample.   Kinyua et al.62 
GC-MS, NMR Analysis of seized material. Ladroue et al.63 
GC-FID Biocatalytic synthesis of chiral species. Martínez-Montero 
et al.64 
GC-MS, LC-Orbitrap-MS Detection in seized samples. Odoardi et al.65 
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LC-MS/MS Detection in hair. Palamar et al.66 
GC-MS Detection in biofluids.  Poklis et al.67 
LC-MS/MS Detection in hair. Salomone et al.68 
LC-TOF-MS Application to analyses of authentic urine samples. Sundström et al.69 
and Heikman et 
al.70 
LC-QqQ-MS/MS Method development for blood analysis. Vaiano et al.71 
LC-TOF-MS Method development for blood analysis. Woldegebriel et 
al.72 
GC-MS, LC-DAD Analysis of submitted samples to drug checking service. Brunt et al.73 
LC-Q-TOF-MS, LC-
Orbitrap-MS 
Analysis of wastewater samples. Causanilles et al.74 
Not reported Detection in biofluids. Nugteren-Van 
Lonkhuyzen et al.75 
LC-Orbitrap-MS Method development for hair analysis. Odoardi et al.76 
GC-FID Biocatalytic synthesis of chiral species. Pushpanath et al.77 
SFC, Q-TOF-MS, UV Differentiation between regioisomers. Segawa et al.78 
LC-UV Method development for chiral separation. Taschwer et al.79 
PALME, LC-MS Method development for plasma and blood analysis. Vårdal et al.80 
GC-MS, LC-UV Differentiation between regioisomers. Weiß et al.81 
Immunoanalysis, LC-MS 
(various) 
Blood and oral fluid analysis of Belgian driving under 
the influence of drugs population.  
Wille et al.82 
GC-MS Detection in urine sample. Wolf et al.83 
 
a XRD: X-ray diffraction; GC: gas chromatography; MS: mass spectrometry; IR: infrared; NMR: nuclear 
magnetic resonance spectroscopy; LC: liquid chromatography (various forms); FL: fluorescence; TOF: time-
of-flight; EI: electron ionization; CI: chemical ionization; DAD: diode array detector; ESI: electrospray 
ionization; PS: paper spray; CE: capillary electrophoresis; CZE: capillary zone electrophoresis; Q: 
quadrupole; QqQ: triple quadrupole; PTR: proton-transfer-reaction; LIF: laser induced fluorescence; MEKC: 
micellar electrokinetic capillary chromatography; IT: linear ion trap; HS: head space; SRI: selective reagent 
ionization; TLC: thin-layer chromatography; NPD: nitrogen-phosphorus detector; EMIT: enzyme multiplied 
immunoassay technique; FID: flame ionization detector; SFC: supercritical fluid chromatography; CEC: 
capillary electrochromatography; PALME: Parallel artificial liquid membrane extraction.  
 
 
 
References 
 
1. Marthi K, Ács M, Pokol G, Tomor K, Eröss-Kiss K. DSC studies on the polymorphism and 
pseudopolymorphism of pharmaceutical substances. A complex system for studying physico-
chemical behavior of binary mixtures. J Therm Anal 1992;38:1017-25. doi:10.1007/BF01979435. 
 
2. Podányi B. Selegilin és rokon vegyületeinek vizsgálata NMR spektroszkópiával. Acta 
Pharm Hung 1992;62:218-24.  
 
3. Simon K, Böcskei Z, Török Z. Selegilin és rokon vegyületek vizsgálata 
röntgendiffrakcióval. Acta Pharm Hung 1992;62:225-30.  
39th ECDD (2017) Agenda item 4.3   4-FA  
 
 
 
Page 39 of 46 
 
4. Lajtha A, Sershen H, Cooper T, Hashim A, Gaal J. Metabolism of (-)-deprenyl and PF-(-)-
deprenyl in brain after central and peripheral administration. Neurochem Res 1996;21:1155-60. 
doi:10.1007/BF02532389. 
 
5. Rösner P, Quednow B, Girreser U, Junge T. Isomeric fluoro-methoxy-phenylalkylamines: 
a new series of controlled-substance analogues (designer drugs). Forensic Sci Int 2005;148:143-
56. doi:10.1016/j.forsciint.2004.05.003. 
 
6. Kikura-Hanajiri R, Kawamura M, Uchiyama N, Ogata J, Kamakura H, Saisho K et al. 
Analytical data of designated substances (Shitei-Yakubutsu) controlled by the pharmaceutical 
affairs law in Japan, part I: GC-MS and LC-MS. Yakugaku Zasshi 2008;128:971-9. 
doi:10.1248/yakushi.128.971. 
 
7. Min JZ, Shimizu Y, Toyo'oka T, Inagaki S, Kikura-Hanajiri R, Goda Y. Simultaneous 
determination of 11 designated hallucinogenic phenethylamines by ultra-fast liquid 
chromatography with fluorescence detection. J Chromatogr B 2008;873:187-94. 
doi:10.1016/j.jchromb.2008.08.020. 
 
8. Min JZ, Hatanaka S, Toyo'oka T, Inagaki S, Kikura-Hanajiri R, Goda Y. Rapid, sensitive 
and simultaneous determination of fluorescence-labeled designated substances controlled by the 
Pharmaceutical Affairs Law in Japan by ultra-performance liquid chromatography coupled with 
electrospray-ionization time-of-flight mass spectrometry. Anal Bioanal Chem 2009;395:1411-22. 
doi:10.1007/s00216-009-3046-8. 
 
9. Takahashi M, Nagashima M, Suzuki J, Seto T, Yasuda I, Yoshida T. Creation and 
application of psychoactive designer drugs data library using liquid chromatography with 
photodiode array spectrophotometry detector and gas chromatography-mass spectrometry. Talanta 
2009;77:1245-72. doi:10.1016/j.talanta.2008.07.062. 
 
10. Westphal F, Roesner P, Junge T. Differentiation of regioisomeric ring-substituted 
fluorophenethylamines with product ion spectrometry. Forensic Sci Int 2010;194:53-9. 
doi:10.1016/j.forsciint.2009.10.007. 
 
11. Inagaki S, Hirashima H, Taniguchi S, Higashi T, Min JZ, Kikura-Hanajiri R et al. Rapid 
enantiomeric separation and simultaneous determination of phenethylamines by ultra high 
performance liquid chromatography with fluorescence and mass spectrometric detection: 
application to the analysis of illicit drugs distributed in the Japanese market and biological 
samples. Drug Test Anal 2012;4:1001-8. doi:10.1002/dta.1327. 
 
12. Jhang C-S, Lee H, He Y-S, Liu J-T, Lin C-H. Rapid screening and determination of 4-
chloroamphetamine in saliva by paper spray-mass spectrometry and capillary electrophoresis-mass 
spectrometry. Electrophoresis 2012;33:3073-8. doi:10.1002/elps.201200270. 
 
13. Johansen SS, Hansen TM. Isomers of fluoroamphetamines detected in forensic cases in 
Denmark. Int J Legal Med 2012;126:541-7. doi:10.1007/s00414-012-0671-0. 
 
39th ECDD (2017) Agenda item 4.3   4-FA  
 
 
 
Page 40 of 46 
14. Lee H, Jhang C-S, Liu J-T, Lin C-H. Rapid screening and determination of designer drugs 
in saliva by a nib-assisted paper spray-mass spectrometry and separation technique. J Sep Sci 
2012;35:2822-5. doi:10.1002/jssc.201200480. 
 
15. Lichtenberger O. Fluorphenyl- und Fluormethoxyphenylalkylamine und deren 
Anwendung. Patent No. DE102011015842A1, 2012. 
 
16. Mohr S, Weiß JA, Spreitz J, Schmid MG. Chiral separation of new cathinone- and 
amphetamine-related designer drugs by gas chromatography-mass spectrometry using 
trifluoroacetyl-L-prolyl chloride as chiral derivatization reagent. J Chromatogr A 2012;1269:352-
9. doi:10.1016/j.chroma.2012.09.079. 
 
17. Nakanishi K, Miki A, Zaitsu K, Kamata H, Shima N, Kamata T et al. Cross-reactivities of 
various phenethylamine-type designer drugs to immunoassays for amphetamines, with special 
attention to the evaluation of the one-step urine drug test Instant-View, and the Emit assays for use 
in drug enforcement. Forensic Sci Int 2012;217:174-81. doi:10.1016/j.forsciint.2011.11.003. 
 
18. Reitzel LA, Dalsgaard PW, Müller IB, Cornett C. Identification of ten new designer drugs 
by GC-MS, UPLC-QTOF-MS, and NMR as part of a police investigation of a Danish Internet 
company. Drug Test Anal 2012;4:342-54. doi:10.1002/dta.358. 
 
19. Röhrich J, Becker J, Kaufmann T, Zörntlein S, Urban R. Detection of the synthetic drug 4-
fluoroamphetamine (4-FA) in serum and urine. Forensic Sci Int 2012;215:3-7. 
doi:10.1016/j.forsciint.2011.04.004. 
 
20. Rust KY, Baumgartner MR, Dally AM, Kraemer T. Prevalence of new psychoactive 
substances: A retrospective study in hair. Drug Test Anal 2012;4:402-8. doi:10.1002/dta.1338. 
 
21. Shanks KG, Dahn T, Behonick G, Terrell A. Analysis of first and second generation legal 
highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid 
chromatography and time of flight mass spectrometry. J Anal Toxicol 2012;36:360-71. 
doi:10.1093/jat/bks047. 
 
22. Strano-Rossi S, Anzillotti L, Castrignano E, Romolo FS, Chiarotti M. Ultra high 
performance liquid chromatography-electrospray ionization-tandem mass spectrometry screening 
method for direct analysis of designer drugs, "spice" and stimulants in oral fluid. J Chromatogr A 
2012;1258:37-42. doi:10.1016/j.chroma.2012.07.098. 
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